ABSTRACT
The cytotoxicity of two tricarbonyl Mn(I) complexes of the general formula fac-[MnBr(CO)3L] (L = quinoline-2-carboxaldehyde (A) and 8-amino quinoline (B)) towards triple negative breast cancer (MDA-MB-231) was reported. Complexes A and B released CO when exposed to 468 nm light. Compound B has a dose-dependent cytotoxicity, with half maximal inhibitory concentration values of 19.62 µM and 11.43 µM before and after illumination, respectively. Co-treatment of MDA-MB-231 with paclitaxel (30 nM) and complex B (10 µM) resulted in a 50% reduction in cell viability.
Subject(s)
Triple Negative Breast Neoplasms , Cell Survival , Humans , Ligands , Paclitaxel , Triple Negative Breast Neoplasms/drug therapyABSTRACT
Carbon monoxide has recently emerged to promote tissue regeneration, enhance the innate immune system, and have anti-inflammatory and antibacterial properties. While the first generation Ru(II) carbonyl prodrugs (CORM-2 and CORM-3) displayed several beneficial biological effects, a search in the literature shows that little work has been done to address the drawbacks of CORM-2/-3, exploring other CO triggered methods for the next generation Ru(CO)2II based compounds and examining their valuable biological impact. We present a summary of most work related to Ru(II) carbon monoxide-releasing molecules, protein bioconjugation, and antibacterial and anti-inflammatory properties.
